New hope to shield hearts from chemo damage
NCT ID NCT06491680
Summary
This study is testing if a drug called dapagliflozin can protect the heart from damage caused by a common and powerful type of breast cancer chemotherapy. It will involve 40 breast cancer patients who are scheduled to receive anthracycline chemotherapy. The goal is to see if taking dapagliflozin alongside chemotherapy can help prevent heart problems, a known serious side effect of these cancer treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Al demerdash hospital at oncology departement
RECRUITINGCairo, Cairo Governorate, 202, Egypt
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.